BioAtla develops Conditionally Active Biologics (CABs) that are engineered to activate selectively in the tumor microenvironment, enhancing tumor selectivity and reducing on-target toxicity. This technology aims to improve the therapeutic index of cancer treatments, providing safer and more effective immunotherapies.
Funding
$9.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional cancer treatments often lack the ability to distinguish between cancerous and healthy tissue, leading to significant on-target toxicity and limiting the effectiveness of immunotherapies. This lack of selectivity can result in severe side effects and reduced therapeutic benefits for patients.
Solution
BioAtla develops Conditionally Active Biologics (CABs), a platform for creating targeted cancer therapeutics. CABs are designed to be activated or inactivated based on specific physiological conditions found in the tumor microenvironment. This conditional activity enhances tumor selectivity, reducing off-target effects and improving the therapeutic index of cancer treatments. By exploiting the unique characteristics of diseased tissue, CABs aim to deliver safer and more effective immunotherapies that minimize harm to healthy cells while maximizing anti-tumor activity. The Comprehensive Integrated Antibody Optimization (CIAO!™) further refines the antibodies for optimal performance.
Target Audience
The primary target audience includes pharmaceutical companies and clinical researchers focused on developing and improving cancer immunotherapies with enhanced safety and efficacy profiles.
Features
- Conditionally Active Biologics (CABs) that are activated or inactivated under defined physiological conditions within the tumor microenvironment.
- Enhanced tumor selectivity, reducing on-target toxicity and improving the therapeutic index.
- Comprehensive Integrated Antibody Optimization (CIAO!™) platform for antibody refinement.